FeraSpin R

Liver imaging MRI agent

Order no:

FeraSpin R MRI agent (1 x 5 injections): 130 - 095 - 138
FeraSpin R MRI agent (5 x 5 injections): 130 - 095 - 139

price per item:
Excluding VAT and shipping costs

FeraSpinTM R is based on the clinically proven Ferucarbotran and forms the basis of all products within the FeraSpin Series. FeraSpin R is rapidly taken up by liver and spleen macrophages.

Viscover's proven superparamagnetic iron oxide (SPIO) nanoparticle agent:

  • Consists of nanoparticles with sizes ranging from 10-90 nanometers
  • Is rapidly taken up by macrophages in the liver and spleen
  • Delivers optimal T2/T2* contrast
  • FeraSpin R is Viscover's leading liver imaging agent for T2-weighted MRI

Apply FeraSpin R SPIO nanoparticles to:

  • Effectively visualize spleen, liver and liver tumor morphology in excellent detail in T1-weighted MR images
  • Study nanoparticle physiology with ease
  • Rely on a substance well-proven in clinical practice
Physico-chemical properties and structure

Mean particle size (hydrodynamic diameter):

60 nm

Particle size range:

10 - 90 nm

Relaxivity (37 °C, 1.41 T)
In water:

r1 = 10 L mmol-1 s-1
r2 = 185 L mmol-1 s-1

Relaxivity (37 °C, 1.5 T, clinical device)
In plasma:

r1 = 7 L mmol-1 s-1
r2 = 95 L mmol-1 s-1

In water:

r1 = 9 L mmol-1 s-1
r2 = 61 L mmol-1 s-1

Schematic diagram of a FeraSpin R nanoparticle

Schematic diagram of a FeraSpin R nanoparticle

FeraSpin R MRI of the liver
Axial T2-weighted MR images of a mouse before (left) and after (right) injection of FeraSpin R. Accumulation of the agent inliver Kupffer cells leads to hypointensity of healthy liver tissue and renders the tumor white and highly visible.
Selected references
  1. Schwab, L. et al. (2014) Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage, Nat. Med. 20: 648-654.
  2. Murakami,T. et al. (2001) Evaluation of regional liver damage by magnetic resonance imaging with superparamagnetic iron oxide in rat liver. Dig. Dis. Sci. 46: 148-155.
  3. Lawaczeck, R. et al. (1997) magnetic iron oxide particle coated with carboxydextran for parental administration and liver contrasting. Pre-clinical profile of SHU555A. Acta Radiol 38: 584-597.
  4. Weigl, F. et al. (2017) Determination of the Total Circulating Blood Volume using Magnetic Particle Spectroscopy. Int. J. Mag. Part. Imag. 3(1).
Further information